

2019 Texas Taiwanese Biotechnology **Association Symposium**

Accelerating the Innovation of Biomedicine by Artificial Intelligence

For Launch!




















Table of Contents

• About	2
Welcome Message	3
Venue of 2019 TTBA Symposium	4
• Parking information	5
• Agenda	6
• Keynotes	9
China Medical University Faculty Recruitment	12
• BioGroup	13
National Applied Research Laboratories	14
 Panel I: How to Survive in the Industry? – Behind the Story 	15
Panel II: How to Plan for a Successful Academic Career	17
Panel III: Beyond the Bench	19
Information Session	20
BioLegend Elevator Talk Competition	21
Acknowledgement	22
Organizing Committee	23
• Supporters	26

About

Texas Taiwanese Biotechnology Association



Texas Taiwanese Biotechnology Association (TTBA) was established by groups of vibrant Taiwanese graduate students and young professionals from top-notch biomedical research institutions in Texas. Our goal is to facilitate intellectual conversation and professional networking among young Taiwanese biomedical talents and foster their career development in the US and Taiwan.

The aims of TTBA symposium are to:

- Encourage in-depth communication, networking, and collaboration among the Taiwanese scientific communities.
- Provide a conversation platform to facilitate interdisciplinary discussion about the current and future scientific landscape.
- Provide opportunities for well-established Taiwanese scientists and entrepreneurs to share global views and experiences in career development.

Welcome Message

Dear TTBA Sponsors, Supporters, Members and Friends,

It is my honor to welcome all of you to attend the 5th TTBA symposium in 2019 on behalf of TTBA.

TTBA was founded in 2014 and ran by groups of Taiwanese students, young talents and professionals in various biosciences fields in five major Texas cities including Houston, Austin, Dallas, College Station, and San Antonio. Our mission is to strengthen the bonds among Taiwanese researchers, scientists, professionals, entrepreneurs and leaders in biosciences fields, and pave the paths for the career development of students. Given the limited resources in Texas comparing to the biotech/biomedical clusters on the East Coast and West Coast, TTBA has strived to hold high-quality events to achieve our mission. We have held 4 TTBA annual symposiums and 20+ webinars, and co-hosted 4 Science, Engineering and Technology Seminar (SETS) conferences. Totally, we have invited 90+ speakers from academia, industry, and government and successfully connected 200+ young people.

This year, we come back to Houston, where our first annual symposium was held, and hold our fifth annual symposium. There are 3 keynote sessions, 3 panel discussions, one recruitment talk, the parallel experience sharing event and the elevator talk competition with good cash prizes. I believe all of you would be able to learn a lot from those fabulous speakers, session presenters, and conversations with all attendees to expand your connections, explore your future career, prepare for your next step, and make your dream come true.

I would like to thank all the speakers for accepting our invitations and traveling to Houston to share your priceless insights into the fields and invaluable experiences about your journey, which are much helpful to attendees. Also, such a fantastic symposium cannot come true without our brilliant 2019 TTBA Symposium Executive Committee. They have been working so hard for 7+ months and have overcome numerous challenges to achieve all the tasks. In addition, the symposium would be impossible without all the supports from our generous sponsors as well as our partners, Ministry of Science and Technology of Taiwan (MOST), Taipei Economic & Cultural Office (TECO) in Houston, and Baylor College of Medicine. I would like to thank all the people who have been supporting TTBA in every aspect. TTBA cannot continue to thrive without your support and participation. I appreciate your help very much.

I am proud of being part of TTBA and I hope you feel proud of yourself for joining such a great symposium as well. I am very much looking forward to meeting you at 2019 TTBA symposium.

Sincerely, Chih-Hsu (Jack) Lin

Chih-Hss Litz


President, Texas Taiwanese Biotechnology Association

Venue of 2019 TTBA Symposium

Alkek building at Baylor College of Medicine

6450 East Cullen St, Houston, TX 77030

Alkek Building 3rd Floor



Parking Information

Texas Medical Center Parking Garage 4 & 6


Parking rate:

0 – 1 Hour **\$5**

1 Hour – 2 Hours **\$8**

2 Hours - 4 Hours **\$10**

4 Hours - 24 Hours **\$13**





Agenda

SATURDAY, July 13, 2019

@ Rm N315, Alkek Building 12:40 pm	12:30 pm	Opening Remarks	
Recruitment @ Rm N315, Alkek Building 1:20 pm Academic Keynote: My Journey as a Scientist @ Rm N315, Alkek Building Professor of Neurology, University of California at San Francisco 2:20 pm Panel I: How to Survive in the Industry? – Behind the Story @ Rm N315, Alkek Building Wan-Hung (Joy) Lee, Ph.D. Scientist I, Translational Biology Dicerna Pharmaceuticals, MA, USA Linya Wang, Ph.D. Research Scientist, Drug Discovery R&D Department AbVision Inc., CA, USA 3:20 pm Coffee Break @ 3rd Floor Coffee Corner, Alkek Building 3:40 pm Industry Keynote: Cancer Immunology and Advanced Technology: Coffee Executive Officer, President and Coffounder	•		
@ Rm N315, Alkek Building 1:20 pm	12:40 pm		<u> </u>
My Journey as a Scientist @ Rm N315, Alkek Building Professor of Neurology, University of California at San Francisco 2:20 pm Panel I: How to Survive in the Industry? – Behind the Story @ Rm N315, Alkek Building Wan-Hung (Joy) Lee, Ph.D. Scientist I, Translational Biology Dicerna Pharmaceuticals, MA, USA Linya Wang, Ph.D. Research Scientist, Drug Discovery R&D Department AbVision Inc., CA, USA 3:20 pm Coffee Break @ 3rd Floor Coffee Corner, Alkek Building 3:40 pm Industry Keynote: Cancer Immunology and Advanced Technology: Chief Executive Officer, President and Coffounder		@ Rm N315, Alkek Building	President, China Medical University
@ Rm N315, Alkek Building Panel I:	1:20 pm	Academic Keynote:	Ying-Hui Fu, Ph.D.
2:20 pm Panel I: How to Survive in the Industry? – Behind the Story @ Rm N315, Alkek Building Wan-Hung (Joy) Lee, Ph.D. Scientist I, Translational Biology Dicerna Pharmaceuticals, MA, USA Linya Wang, Ph.D. Research Scientist, Drug Discovery R&D Department AbVision Inc., CA, USA 3:20 pm Coffee Break @ 3 rd Floor Coffee Corner, Alkek Building 3:40 pm Industry Keynote: Cancer Immunology and Advanced Technology: Chief Executive Officer, President and Coffounder		My Journey as a Scientist	Professor of Neurology,
How to Survive in the Industry? – Behind the Story @ Rm N315, Alkek Building Wan-Hung (Joy) Lee, Ph.D. Scientist I, Translational Biology Dicerna Pharmaceuticals, MA, USA Linya Wang, Ph.D. Research Scientist, Drug Discovery R&D Department AbVision Inc., CA, USA 3:20 pm Coffee Break @ 3rd Floor Coffee Corner, Alkek Building 3:40 pm Industry Keynote: Cancer Immunology and Advanced Technology: Chief Executive Officer, President and Coffounder		@ Rm N315, Alkek Building	University of California at San Francisco
Behind the Story @ Rm N315, Alkek Building Wan-Hung (Joy) Lee, Ph.D. Scientist I, Translational Biology Dicerna Pharmaceuticals, MA, USA Linya Wang, Ph.D. Research Scientist, Drug Discovery R&D Department AbVision Inc., CA, USA 3:20 pm Coffee Break @ 3rd Floor Coffee Corner, Alkek Building 3:40 pm Industry Keynote: Cancer Immunology and Advanced Technology: Chief Executive Officer, President and Cofficer Founder	2:20 pm	Panel I:	Sean C. Chang, Ph.D.
@ Rm N315, Alkek Building Wan-Hung (Joy) Lee, Ph.D. Scientist I, Translational Biology Dicerna Pharmaceuticals, MA, USA Linya Wang, Ph.D. Research Scientist, Drug Discovery R&D Department AbVision Inc., CA, USA 3:20 pm Coffee Break @ 3rd Floor Coffee Corner, Alkek Building 3:40 pm Industry Keynote: Cancer Immunology and Advanced Technology: Chief Executive Officer, President and Coffounder		How to Survive in the Industry? -	Process Development Scientist
Wan-Hung (Joy) Lee, Ph.D. Scientist I, Translational Biology Dicerna Pharmaceuticals, MA, USA Linya Wang, Ph.D. Research Scientist, Drug Discovery R&D Department AbVision Inc., CA, USA 3:20 pm Coffee Break @ 3'd Floor Coffee Corner, Alkek Building 3:40 pm Industry Keynote: Cancer Immunology and Advanced Technology: Chief Executive Officer, President and Cofficer Founder		Behind the Story	Poseida Therapeutics, CA, USA
Scientist I, Translational Biology Dicerna Pharmaceuticals, MA, USA Linya Wang, Ph.D. Research Scientist, Drug Discovery R&D Department AbVision Inc., CA, USA 3:20 pm Coffee Break @ 3 rd Floor Coffee Corner, Alkek Building 3:40 pm Industry Keynote: Cancer Immunology and Advanced Technology: Chief Executive Officer, President and Coffounder		@ Rm N315, Alkek Building	
Dicerna Pharmaceuticals, MA, USA Linya Wang, Ph.D. Research Scientist, Drug Discovery R&D Department AbVision Inc., CA, USA 3:20 pm Coffee Break @ 3rd Floor Coffee Corner, Alkek Building 3:40 pm Industry Keynote: Cancer Immunology and Advanced Technology: Chief Executive Officer, President and Cofficer Founder			Wan-Hung (Joy) Lee, Ph.D.
Linya Wang, Ph.D. Research Scientist, Drug Discovery R&D Department AbVision Inc., CA, USA 3:20 pm Coffee Break @ 3 rd Floor Coffee Corner, Alkek Building 3:40 pm Industry Keynote: Cancer Immunology and Advanced Technology: Chief Executive Officer, President and Cofficer Founder			Scientist I, Translational Biology
Research Scientist, Drug Discovery R&D Department AbVision Inc., CA, USA 3:20 pm Coffee Break @ 3 rd Floor Coffee Corner, Alkek Building 3:40 pm Industry Keynote: Cancer Immunology and Advanced Technology: Chief Executive Officer, President and Cofficer Founder			Dicerna Pharmaceuticals, MA, USA
3:20 pm Coffee Break @ 3 rd Floor Coffee Corner, Alkek Building 3:40 pm Industry Keynote: Cancer Immunology and Advanced Technology: Conder Department AbVision Inc., CA, USA Sonny Hsiao, Ph.D. Chief Executive Officer, President and Conference of Founder			Linya Wang, Ph.D.
3:20 pm Coffee Break @ 3 rd Floor Coffee Corner, Alkek Building 3:40 pm Industry Keynote: Sonny Hsiao, Ph.D. Cancer Immunology and Advanced Technology: Founder			
@ 3 rd Floor Coffee Corner, Alkek Building 3:40 pm Industry Keynote: Sonny Hsiao, Ph.D. Cancer Immunology and Advanced Technology: Founder			AbVision Inc., CA, USA
3:40 pm Industry Keynote: Sonny Hsiao, Ph.D. Cancer Immunology and Advanced Technology: Founder Power of the Control of the	3:20 pm	Coffee Break	
Cancer Immunology and Chief Executive Officer, President and Control Advanced Technology: Advanced Technology: Founder			
Advanced Technology: Founder	3:40 pm	Industry Keynote:	Sonny Hsiao, Ph.D.
Opportunities at the Intersections Acepodia, Inc.			Chief Executive Officer, President and Co Founder
		Opportunities at the Intersections	Acepodia, Inc.




SATURDAY, July 13, 2019 (cont'd)

4:40 pm	Panel II:	Dung-Fang Lee, Ph.D.		
	How to Plan for a Successful Academic Career	Assistant Professor, Department of Integrative Biology and Pharmacology,		
	@ Rm N315, Alkek Building	UT Health Science Center at Houston, TX, USA		
		Hui-Chen Lu, Ph.D.		
		Professor, Director and Gill Chair for Linda and Jack Gill Center of Neuroscience, Department of Psychological & Brain Sciences,		
		Indiana University, IN, USA		
		Kuang-Lei Tsai, Ph.D.		
		Assistant Professor, Department of Biochemistry and Molecular Biology,		
		UT Health Science Center at Houston, TX, USA		
5:40 pm	Elevator Talk Competition			
, , , , , , , , , , , , , , , , , , ,	@ Rm N315, Alkek Building			
7:00 pm	Reception Dinner			
	@ 2 nd Floor Coffee Corner,			
	Alkek Building			
7:50 pm	BioGroup	Hsinyu Lee, Ph.D.		
	@ Rm N315, Alkek Building	Professor, Department of Life Science and Department of Electrical Engineering, National Taiwan University, Taipei, Taiwan		
8:00 pm	Information Session			
	Group 1: Entrepreneurship	Group 3: Biotech - Non R&D		
	@ Rm N317, Alkek Building	@ Rm N311, Alkek Building		
	Group 2: Academia	Group 4: Biotech - R&D		

@ Rm N315, Alkek Building

@ Rm N302, Alkek Building



SUNDAY, July 14, 2019

8:30 am	Breakfast	
	@ 3 rd Floor Coffee Corner,	
	Alkek Building	
9:00 am	Remarks	Liang-Gee Chen, Ph.D.
	@ Rm N315, Alkek Building	Minister
		MOST
9:10 am	HPC & Al for Biomedical Research	Fang-Pang Lin, Ph.D.
	Q&A	Senior researcher
	@ Rm N315, Alkek Building	NARLabs
9:30 am	Break (Group Photo)	
9:40 am	Artificial Intelligence Keynote:	Terrence Chen, Ph.D.
	Al in Medical Imaging	Chief Executive Officer
	@ Rm N315, Alkek Building	UII America, Inc.
10:40 am	Panel III:	Rei Ting Ling
	Beyond the Bench	Regional Director of Business
	@ Rm N315, Alkek Building	Development,
		TCI Co., Ltd., Utah, USA
		Pao-Chen Li, Ph.D.
		Clinical Research Scientist,
		Nektar Therapeutics, CA, USA
		Maurice Shen, Ph.D.
		Head of Academic Relations,
		BenchSci in Toronto, Canada
11:40 am	Award Ceremony and Closing Remarks	
	@ Rm N315, Alkek Building	
12:10 pm	Networking Luncheon	
	@ 3 rd Floor Coffee Corner, Alkek Building	

Academic Keynote

My Journey as a Scientist



Ying-Hui Fu, Ph.D. 傅姿惠

Professor, Department of Neurology University of California at San Francisco, CA, USA

My research focus has been using human genetics to identify mutations that contribute to neurological conditions and sleep behaviors and then to characterize the corresponding wild-type and mutant proteins. Animal models including mouse and fly are used to recapitulate human conditions via the generation of mutation-carrying animals. In addition, in vitro experiments using cell culture, cellular biology, biochemistry, and proteomics are applied to gain understanding of new aspects of normal biology as well as molecular mechanisms of diseases and unusual sleep behaviors. Each gene that we identify provides new insights into the overall mechanism of complex pathways involved in each condition. This approach has been extremely fruitful for us in revealing the regulatory pathways of human sleep behaviors. The dominant mutations that we have identified in human repeatedly provide significant and unique insights into these pathways that could not be obtained using other traditional animal modeling approaches. To further deepen our understanding of the regulatory mechanisms of human sleep duration and efficiency at the neuro-circuitry level, we are applying emerging neuroscience technologies in our research. This will significantly expand the potential for reaching our ultimate goal of helping people obtain better health and better aging through better sleep.

Industry Keynote

Cancer Immunology and Advanced Technology: Opportunities at the Intersections



Sonny Hsiao, Ph.D. 蕭世嘉

Chief Executive Officer, President and Co-Founder Acepodia, Inc.

Dr. Hsiao is the Chief Executive Officer, President and Co-Founder at Acepodia. Dr. Hsiao has extensive research experiences in immune cell therapies, which lead to the discovery of components of ACC™ (Antibody-Cell Conjugation) technology to the invention of the novel cellular immunotherapy, ACE™ (Antibody-Cell Conjugation Effector cells). Dr. Hsiao earned his BS in Chemistry from National Taiwan University, and his PhD in Chemistry and Molecular Cell Biology from the University of California, Berkeley.

Artificial Intelligence Keynote

AI in Medical Imaging



Terrence Chen, Ph.D.

Chief Executive Officer
UII America, Inc., MA, USA

Terrence Chen received his PhD in Computer Science from the University of Illinois at Urbana-Champaign (UIUC) in 2006. He received a M.S. in Computer Science from UIUC in 2002 and a B.S. in Computer Science and Information Engineering from National Taiwan University in 1998. He is currently CEO of UII America, Inc., a company focusing on empowering medical scanners, doctors, radiologists, and Healthcare providers with state-of-the-art AI research and development. Before joining UII America, Inc., Dr. Chen was Senior Director of Computer Vision Technologies, Medical Imaging Technologies at Siemens Healthcare. In Siemens, he led an R&D team working on computer vision and Machine Learning technologies for Healthcare, including image-guided interventions, and AI-driven intelligent machines for Healthcare. He has more than 60 patents and published more than 50 papers in leading conferences and journals in Computer Vision, Machine Learning, and Medical Imaging, including Thomas Edison Patent Award in 2018, best paper award in VARVAI (ECCV workshop) 2016, and finalist of the best paper award in Medical Robotics & CAI Systems in MICCAI 2011. Much of his research results in differentiated clinical product solutions.




China Medical University Faculty Recruitment



Mien-Chie Hung, Ph.D. 洪明奇

President
China Medical University, Taichung, Taiwan

Mien-Chie Hung, Ph.D. is the President for China Medical University in Taichung, Taiwan. He was vice president for basic research and professor and chair of the Department of Molecular and Cellular Oncology at The University of Texas MD Anderson Cancer Center. Dr. Hung is a basic scientist with a keen translational vision and especially his recent research effort has significantly contributed to understanding the biology of cancer and to developing combinational cancer therapies to overcome resistance. Up to date, Dr. Hung has published more than 520 peer-reviewed articles, of which over 110 were published in journals with impact factor 10 or above. His lifetime h-index surpasses 110. He is one of members of Selection Committee for Tang Prize in Biopharmaceutical Science category and is one of the founding Editorial Members for Cancer Cell, serves as Editorin-chief for American Journal for Cancer Research (2015-2017) and Senior Editor for Cancer Research (American Association for Cancer Research, 2018-2021). Dr. Hung was inducted as an Academician of the Academia Sinica in Taiwan in 2002 and as a Fellow in Biological Sciences section, American Association for the Advancement of Science in 2010. His laboratory has a long term commitment to the following research areas: 1) discovery of novel functionality of epidermal growth factor receptor (EGFR) family which may provide useful insight to understand cancer formation and development; 2) identification of crosstalks of signal pathways/networks in cancer cells and tumor microenvironment which could potentially predict resistance to target therapy; 3) development of marker-guided targeted therapy including PARP and EGFR inhibitors, immune checkpoint therapy which will effectively treat cancer patients.



BioGroup



Hsinyu Lee, Ph.D. 李心予

Professor, Department of Life Science and Department of Electrical Engineering, Director of PMBM, National Taiwan University, Taipei, Taiwan

Dr. Hsinyu Lee received his PhD degree from University of California, San Francisco. He is currently the Director of PMBM and a jointed professor in the Department of Life Science and Department of Electrical Engineering at National Taiwan University. His research focuses on using human endothelial cell as a model system to investigate the molecular and physiological functions of lysophospholipids, LPA and S1P. The research results demonstrated that LPLs might be important regulators of blood vessel formation. In his recent works, he found that LPLs are potent stimulators for the expression of cell adhesion molecules and chemotatic factors of endothelial cells.

Website: http://www.lifescience.ntu.edu.tw/2016/faculty HsinyuLee.html?lang=en

National Applied Research Laboratories



Fang-Pang Lin, Ph.D. 林芳邦

Senior Research Scientist, National Center for High Performance Computing, National Applied Research Laboratories, Taipei City, Taiwan

Dr. Fang-Pang Lin has crucial contribution in Cloud Computing and System Integration at National Center for High Performance Computing. He was one of the key developers for developing the national cyber-infrastructure of Taiwan, namely Knowledge Innovation National Grid. He co-founded the Global Lake Ecological Observational Network and Global Coral Reef Environmental Observational Network. His major research focuses on cyberinfrastructure for long term environmental and ecological observation. Recent development includes Taiwan Earth Science Observatory Knowledgebase, EU FP7 Fish4Knowledge collaboration, real-time wide area flood monitoring and government big data. The efforts also lead to US-East Asia collaborations to enable transnational cyberinfrastructure applications, which based on shared software defined systems applying to issues on disaster management, environmental monitoring and simulation, and smart cities. He was the winner of 2006 Outstanding Achievement Award in Science and Technology, the Executive Yuan of Taiwan.

Research Areas

- 1. Fluid dynamics, shape optimization
- 2. Numerical methods, mesh generation
- 3. Parallel and distributed computing in cyberinfrastructure

Potential Collaboration Topics

- 1. Cyberinfrastructure for IoT
- 2. Al acceleration through accelerator, e.g. GPU, FPGA
- 3. Data streaming & management

Panel 1: How to Survive in the Industry? – Behind the Story



Sean C. Chang, Ph.D. 章齊軒
Process Development Scientist

Poseida Therapeutics, CA, USA

Sean Chang received his Ph.D. in Integrative Molecular and Biomedical Sciences from Baylor College of Medicine. Under the

supervision of Dr. Jeffrey Rosen, he discovered the molecular mechanisms underlying the radiation resistance of breast cancer stem cells using preclinical syngeneic mouse models. He then further studied the relationship between chemotherapy efficacy and T cell infiltration in solid tumors during his postdoctoral training. Sean began his career in industry as a Cell Biology R&D Scientist at Thermo Fisher Scientific in 2016. He worked on multiple product developments to facilitate next generation cell therapy workflow, including improving gene editing efficiency in T cells and developing new automation systems to support both autologous and allogeneic cell therapies. In addition to scientific works, as a project leader, Sean worked closely with other business sectors to ensure a successful product launch. He also played an important role to support business development, technical consultation, and customer facing to increase cell therapy business revenue. Sean is now a Process Development Scientist at Poseida Therapeutics, a clinical-stage biopharmaceutical company committed to developing novel cell therapy products.



Wan-Hung (Joy) Lee, Ph.D. 李宛鴻

Scientist I, Translational Biology Dicerna Pharmaceuticals, MA, USA

Joy obtained her doctoral degree in Molecular and Cellular Biochemistry from Indiana University Bloomington in 2017. Her PhD thesis applied pharmacology and rodent animal models to

investigate the involvement of PSD95-nNOS-NOS1AP protein-protein interactions downstream of NMDA receptor in chronic pain. After her graduation, she joined a small startup company, Anagin, in Indianapolis, IN continuing her efforts in developing small molecule inhibitors targeting the same PSD95-nNOS-NOS1AP protein-protein interface for treating wide range of neurological diseases. Joy recently joined Dicerna, an RNAi therapy company, focusing on developing animal disease model to identify potential therapeutic target for but not limited to rare genetic liver diseases.



Linya Wang, Ph.D. 王林雅

Research Scientist, Drug Discovery R&D Department AbVision Inc., CA, USA

Dr. Wang obtained her PhD degree in Microbiology at National Taiwan University. The main project was to investigate the Hepatitis C virus RNA regulating its replication via utilizing cellular

protein for RNA circulation. Her postdoc experience was completed in University of Southern California, Institute of Molecular Microbiology and Immunology. Dr. Wang continued to study the intracellular membrane system that supports Hepatitis C virus RNA replication. Currently, she joined a startup company, AbVision Inc. The job duty includes therapeutic antibody discovery, production, and characterization.

Panel II: How to Plan for a Successful Academic Career



Dung-Fang Lee, Ph.D. 李東芳

Assistant Professor, Department of Integrative Biology and Pharmacology.

UT Health Science Center at Houston, TX, USA

the importance of genes in human disease pathogenesis and offer powerful insights into their roles in human disease pathogenesis. Prof. Lee's research is dedicated to understanding cancer pathological mechanisms by iPSC disease models. As a biomedical investigator, with a significant background and training in stem cell and cancer biology, he has been fortunate enough to design and merge his laboratory research and clinical interests. Dr. Lee recognizes the need for improving our understanding of osteosarcomagenesis and the identification of therapeutic agents for patient treatment. His laboratory has tremendous interest and experience in collaborating clinical physicians to merge innovative iPSC disease models and patient-derived resources such as PDXs, patient specimens, and TCGA database, towards garnering molecular insights into osteosarcoma initiation, development and therapeutic resistance and translating these findings towards testing novel therapeutic interventions for these




bone malignancies.

Hui-Chen Lu, Ph.D. 盧慧珍

Professor, Director and Gill Chair for Linda and Jack Gill Center of Neuroscience, Department of Psychological & Brain Sciences, Indiana University, IN, USA

Prof. Lu acquired a broad background in signaling cascades during embryogenesis through her Ph.D. thesis studies with Dr. Gregor

Eichele in embryology and post-doctoral training with Dr. Michael C. Crair in synaptic physiology. During her Ph.D. studies, Prof. Lu mastered molecular biology, histology, and surgical skills for grafting embryonic tissue. As a postdoctoral fellow in neuroscience, she became proficient in various electrophysiological techniques and carried out extensive studies with transgenic mice. Currently, Prof. Lu's team aims to elucidate the signaling cascades underlying neural circuit connections during brain development, to understand how sensory experiences affect neural circuit wiring and cognitive behaviors, and how neural circuits maintain their health during aging process. These interests are driven by a growing appreciation that mis-wiring of neuronal circuits during early life is likely to be a major cause of neurological disorders, including autism, schizophrenia, and congenital epilepsy, while dysfunctional neural networks lead to degeneration and dementia.



Kuang-Lei Tsai, Ph.D. 蔡光磊

Assistant Professor, Department of Biochemistry and Molecular Biology,

UT Health Science Center at Houston, TX, USA

Prof. Tsai's research interests focus on the use of single-particle cryo-electron microscopy (cryo-EM) and computational image

analysis to determine the structures of macromolecular complexes that carry out key biological functions, such as transcription, DNA replication, and gene regulation. In particular, He is interested in the functional relevance of large-scale conformational changes in macromolecular complexes, and he has significant expertise in specimen preparation and image analysis geared toward acquisition of 2- and 3-dimensional structural information that provide insight into physiologically significant quaternary structures. His research group utilizes advanced cryo-EM, X-ray crystallography and biochemical approaches to understand how dysfunction of specific macromolecular complexes drives cancer cell development. Dr. Tsai also successfully collaborated with several other laboratories studying different research projects, including ribonucleotide reductase, protein cage, and Augmin complex. Moreover, his expertise in single-particle cryo-EM and experience in structural biology provide strong support on structural studies of protein-lncRNA complexes and membrane proteins.

Panel III: Beyond the bench



Rei Ting Ling 凌睿廷

Regional Director of Business Development, TCI Co., Ltd., Utah, USA

Development at TCI. He values the importance of competitive advantages created through innovation and cross-disciplinary integration. At TCI, Rei has generated more than 16 Million US dollars of revenue in 3 years of his career as a sales representative, and has led the TCI BIOTECH LLC., the subsidiary of TCI Co LLC to grow more than 800% within the first year of the establishment. Rei is an excellent presenter and has a rare talent mix of solid science background, creativity, outgoing sales character, precise marketing insights, and broad spectrum understanding of consumer behavior. He has a passion to challenge the status guo and dreams of possibilities within impossibility.



Pao-Chen Li, Ph.D. 李保蓁

Clinical Research Scientist, Nektar Therapeutics, CA, USA

Pao-Chen has diverse experience from drug discovery as a bench scientist to drug development as a regolaoty project manager and clinical scientist. As a clinical scientist at Nektar Therapeutics, Pao-

Rei is the North American Regional Director of Business


Chen works closely with the medical monitor and cross-functional team on bladder cancer studies for study protocol design, communication with health authorities and investigators, sites initiation and data review. Prior to Nektar, Pao-Chen worked as a regulatory project manager managing the timelines for milestones submissions at Gilead for 9 marketed products and 5 developing products in HIV, inflammation and liver diseases therapeutic areas. Prior to Gilead, she was a drug discovery research scientist program lead at Assembly Biosciences, a small biotech company developing treatments for Hepatitis B virus infected patients. She led cell assay development, high-throughput screening, CRO management, and participated in IND enabling studies. Pao-Chen received her PhD in Molecular Biology at University of Southern California and did her postdoctoral training at Gladstone Institutes, UCSF.

Maurice Shen, Ph.D. 沈彦甫

Head of Academic Relations, BenchSci in Toronto, Canada

Toronto in 2015. His thesis examined the physiological role of a novel dopamine receptor complex, the D1-D2 heteromer, in drug addiction and depression-related behaviors, as well as the associated neuroadapatations. Maurice believes that the current research process can be greatly complemented by the recent advance in machine learning technology. He is dedicated to building a digital research tool that can benefit the scientific community as a whole by speaking to researchers and incorporating their needs into BenchSci.

Information Session



Assistant Professor, Graduate Insitute of Biomedical Sciences Yingcai Young Scholar (英才青年學者),
China Medical University, Taichung, Taiwan

Maurice obtained his PhD. in Pharmacology from the University of

Dr. Liu, Yen-Liang 劉彥良 received his B.S. degree in Life Science and MS degree in Biomedical Engineering from National Taiwan

University. His master's thesis was focused on lung tissue engineering and alveolar angiogenesis. He also participated in clinical research of stem cell therapy for knee cartilage regeneration. In 2018, he received his Ph.D. degree in Biomedical Engineering from the University of Texas at Austin. His research focuses on the instrumentation of an advanced fluorescence microscope and its application in cancer diagnostics. He is also the co-founder of Texas Taiwanese Biotechnology Association (TTBA) and the President of 2017. In 2019, he was awarded the Young Scholar Fellowship Program (Columbus project) and started his laboratory at China Medical University.

LinkedIn: https://www.linkedin.com/in/allen-yl-liu/

Google Scholar: https://scholar.google.com/citations?user=ZZQgPOsAAAAJ&hl=en



BioLegend Elevator Talk Competition

Finalists	Title		
Yi-Ting Chen	Investigating the role of ATRX in osteosarcoma progression		
Chih-Chien Chou	IL-15 deficient colon carcinomas have decreased cytolytic lymphocytes and skewed myeloid cell populations		
Amy Ku	Targeting JAK/STAT Signaling in Human Precancerous Lesions for Breast Cancer Prevention		
Yi-Tang Lee	Environmental input regulates reproductive adaptation via oocyte mitochondrial dynamics		
Grace Hsuan-Chen Liu	Chicken egg - A Swiss army knife for multi-bioassays		
I-Wen Song	3D genome architecture: a new way towards understanding disease pathogenesis		
Yu-Jung Tseng	Hematopoietic system under steady-state and stress conditions		
Wan-Jung Wu	Regulation of intestinal immunity by the individual members of the microbiota		

^{*} Alphabetized by Last Name

Acknowledgement

The 2019 TTBA Symposium is co-organized by *Texas Taiwanese Biotechnology Association (TTBA)* and *Ministry of Science and Technology (MOST), Taiwan, R.O.C.* We would like to thank you for attending our fifth TTBA Symposium.

We also sincerely appreciate all assistance and support from the invited speakers, 2019 Symposium Executive Committee, Taipei Economic and Cultural Office in Houston (TECO-Houston), the Baylor College of Medicine (BCM), BCM TSA, and our symposium supporters.

Special Thanks to:

Officers of TECO-Houston

- General Director Peter Chen
- Director Jiun-Haw Lee, Science and Technology Division
- Director Sophie Chou, Education Division
- Director Patrick Ho, Economic Division

Organizing Committee

President

Chih-Hsu (Jack) Lin, 林之昫, PhD candidate, Baylor College of Medicine

Vice President

Grace Liu, 劉軒辰, PhD candidate, Baylor College of Medicine

Board Members

Amy Ku, 辜千慈, Postdoc, Baylor College of Medicine
Wen-Ling Lin, 林玟伶, PhD candidate, the University of Texas at Austin
Grace Chun-Jung Lin, 林君榕, Postdoc, UT Southwestern Medical Center
Michael Yu-An Kuo, 郭宇安, PhD student, the University of Texas at Austin
Grace Hsuan-Chen Liu, 劉軒辰, PhD candidate, Baylor College of Medicine
Chih-Hsu (Jack) Lin, 林之昫, PhD candidate, Baylor College of Medicine
Sih-Rong Wu, 吳思瑢, PhD candidate, Baylor College of Medicine

Moderators

Grace Hsuan-Chen Liu, 劉軒辰, PhD candidate, Baylor College of Medicine Adam Cheng-Hsin Liu, 劉政昕, PhD candidate, Baylor College of Medicine

Keynote Session Chairs

Chao-Hsien Chen, 陳昭先, PhD candidate, UT MD Anderson Cancer Center Sih-Rong Wu, 吳思瑢, PhD student, Baylor College of Medicine Yi-Ting Chen, 陳宜婷, PhD student, Baylor College of Medicine Chih-Hsu (Jack) Lin, 林之昫, PhD candidate, Baylor College of Medicine

Panel I Chairs

Yu-Jung (Nina) Tseng, 曾郁容, PhD student, Baylor College of Medicine Wan-Jung Wu, 吳宛蓉, PhD student, Baylor College of Medicine

Panel II Chairs

Adam Cheng-Hsin Liu, 劉政昕, PhD candidate, Baylor College of Medicine Shih-Ching Lin, 林世青, PhD candidate, Baylor College of Medicine

Panel III Chairs

Claire Huang, 黃雨湄, Postdoc, Baylor College of Medicine I-Ching Wang, 王意清, PhD student, Baylor College of Medicine

Information Session Chairs

Yu-Jung (Nina) Tseng, 曾郁容, PhD candidate, Baylor College of Medicine Wen-Ling Lin, 林玟伶, PhD candidate, the University of Texas at Austin

BioLegend Elevator Talk Competition Chairs

Sih-Rong Wu, 吳思瑢, PhD candidate, Baylor College of Medicine Yi-Ting Chen, 陳宜婷, PhD candidate, Baylor College of Medicine Monica Meng-Hsuan Wen, 溫孟璇, Postdoc, University of Houston

Website Design

Internet Publicity

Yu-An Kuo, 郭宇安, PhD student, the University of Texas at Austin Fundraising

Chih-Hsu (Jack) Lin, 林之昫, PhD candidate, Baylor College of Medicine
Grace Liu, 劉軒辰, PhD candidate, Baylor College of Medicine
Charles Zeng, 曾煥昌, Research associate, Baylor College of Medicine

Wen-Ling Lin, 林玟伶, PhD candidate, the University of Texas at Austin Po-Hsun Fan, 范博勛, PhD candidate, the University of Texas at Austin Grace Chun-Jung Lin, 林君榕, Postdoc, UT Southwestern Medical Center

Finance

Allen Yen-Liang Liu, 劉彥良, Postdoc, the University of Texas at Austin Wen-Ling Lin, 林玟伶, PhD candidate, the University of Texas at Austin

Public Relation, Promotion

Grace Chun-Jung Lin, 林君榕, Postdoc, UT Southwestern Medical Center Grace Hsuan-Chen Liu, 劉軒辰, PhD candidate, Baylor College of Medicine Chih-Hsu (Jack) Lin, 林之昫, PhD candidate, Baylor College of Medicine Wan-Jung Wu, 吳宛蓉, PhD candidate, Baylor College of Medicine



Flyer and Art Designs

Wan-Jung Wu, 吳宛蓉, PhD candidate, Baylor College of Medicine

Amy Ku, 辜千慈, Postdoc, Baylor College of Medicine

Program Book

Ying-Chun Chou, 周盈君, DrPH candidate, University of Texas Health Science Center

A/V Service

Kevin Lei, 雷適愷, Research Technician, Baylor College of Medicine

Sih-Rong Wu, 吳思瑢, PhD candidate, Baylor College of Medicine

Shih-Ching Lin, 林世青, PhD candidate, Baylor College of Medicine

Photography

Chang-Ru Tsai, 蔡昌儒, Postdoc, UT MD Anderson Cancer Center

Rong-Chi Hu, 胡容綺, PhD student, Baylor College of Medicine

Event Venue

Cheng-Yen Chang, 張正妍, PhD candidate, Baylor College of Medicine

Food Service

James Hwang, 黃善家, Young Professional, UT MD Anderson Cancer Center

Reception Dinner

Amy Ku, 辜千慈, Postdoc, Baylor College of Medicine

Sih-Rong Wu, 吳思瑢, PhD candidate, Baylor College of Medicine

Lodging

Ching Hui (Cindy) Chen, 陳靜慧, Postdoc, Baylor College of Medicine

Transportation

Monica Meng-Hsuan Wen, 溫孟璇, Postdoc, University of Houston

Amy Ku, 辜千慈, Postdoc, Baylor College of Medicine



Symposium supporters

TTBA 2019 Symposium gratefully acknowledge the generosity of our supporters.

PLATINUM LEVEL SUPPORTER





E&M Foundation

Hsiao Family Foundation



GOLD LEVEL SUPPORTER





President 黄登陸

Prof. Ian Lian



SILVER LEVEL SUPPORTER

Prof. Arthur Chang

Dr. Ming-Chi Wu





LiFT [∞]

海外人才歸國橋接方案 2.0 - LIFT, Leaders in Future Trends

計畫背景

海外高階人才交流平台

STEP1 盤點國內跨產業職缺需求:廣 邀產學研機構刊登高階人才職缺。

STEP2 建置 LIFT 海外人才資料庫:政府駐外單位、學人臺商海外網絡組織、國內國際交流中心、LIFT 海外人才基本資料、海外學人自行登錄。

STEP3 整合並設置事前媒合機制:提供線上直接媒合·主動提供潛在合作建議名單。

海外學人返國交流會

舉辦日期:

第一梯次:臺灣時間 6/17-6/28 (12 天)(已結束) 第二梯次:臺灣時間 10/21-11/1 (12 天)

行程內容:

返國媒合形式:

1.綜合型招募博覽會(依產業領域別規劃媒合攤位區) 2.定向邀請一對一面談·線上事前媒合·現場進行深度洽談。

權利義務

返國學人需於公告入選名

單後1個月內與本計畫辦公

室簽定計畫約定書,並於約

定日期內完成「海外學人返

國交流會」報到,若無法完

成簽約及報到者,視同放棄

本方案所有權利。

甄選方式及內容

申請人資格:

- 1.博士或 AI 三年以上海外工作經驗的碩士 2.年齡在 45 歲(含)以下
- 3.近 2 年內最後一份有薪工作不在臺灣 申請方式:
- 1.至 LIFT 人才交流網站線上申請 2.請完整填寫線上申請資料(包含學經歷、自
- 傳等),並上傳佐證文件

審查方式:

共分為初審與複審·將邀請相關領域產學界 專家實質審查·並視需要透過電話或視訊訪 談。

5月

4/1 徵件開始、啟動線上媒合機制

4月中旬 進行事前媒合配對

4/30 收件截止

補助方式及內容

- 1.提供返國交流經濟艙機票補助金。
- 3.活動期間將提供免費食宿及交通安排· 不另支付其他費用。
- 匯集國內重大產業高階人才職缺!
- 提供無國距的互動形式,線上媒合 X 線下交流!
- 提供各學人重要介紹,透過影片或其他形式露出,拓展海外高階人才能見度!

8月

- 整合來自海外 8 大市場、超過 20 個國家的臺灣博士級中高階人才!
- 引進國際新知,激發產業創新!

17万文门共配复/13

7/22 徵件開始、啟動線上媒合機

6/17-6/28 辦理第一梯次

海外學人返國交流會

8月中旬 進行事前媒合配對

8/23 收件截止

9月中上旬 審查/公告

9月 10月

3月中旬網站上線(對外)

4月

6月中旬 開始第二梯次廣宣

10/21-11/1 辦理第二梯次 海外學人返國交流會

海外攬才廣宣,發布國外徵件宣傳

3月

想了解更多訊息,駐休士頓台北經濟文化辦事處科技組

5月中旬 審查/公告

6月

電話:713-840-3855 Email:houston@most.gov.tw

https://lifttaiwan.stpi.narl.org.tw/





前往LIFT線上平台



Feel the joy of high quality, low priced antibodies for Neuroscience and Cell Biology applications.

- Know exactly how much antibody you are buying and make your data more reproducible with microgram sizing.
- Lower pricing enables you to buy more antibody products against more targets.
- · Get more replicates. Get more data.
- BioLegend guarantees product quality with lot-specific quality testing.

Request a discounted small size for testing today at: sales@biolegend.com

Antibody Price Comparison

Product	Clone	Competitor A	BioLegend	Savings
T-bet	4B10	\$4.55/µg	\$1.85/µg	59%
RNA Polymerase II RPB1	8WG16	\$4.59/µg	\$2.35/µg	49%
DNA-PKcs Phospho (Thr2609)	10B1	\$8.70/µg	\$2.50/µg	71%
α-Synuclein Phospho (Ser129)	P-Syn/81A	\$8.38/µg	\$2.85/µg	66%
Pan-Shank	N23B/49	\$4.09/µg	\$1.40/µg	66%
NeuN	1B7	\$4.29/µg	\$2.02/µg	53%


BioLegend is ISO 13485:2016 Certified

Toll-Free Tel (US & Canada): 1.877.BIOLEGEND (246.5343) Tel: 858.768.5800 biolegend.com

08-0077-07



World-Class Quality | Superior Customer Support | Outstanding Value





Hsinchu Science Park Bureau, Ministry of Science and Technology 2 Hsin Ann Road, Hsinchu, Taiwan 30016, R.O.C. Tel:886-3-5773311






廣告




Easily find antibodies from publications.

Free online platform for academia

BenchSci.com







Texas Taiwanese Biotechnology Association



https://www.ttbatw.org



https://www.facebook.com/groups/ttbatw/



https://www.linkedin.com/company/ttba/

